Trial Profile
Phase I, Randomized, Controlled, Third-party Double-blind, Dose Escalating Study of Protexia Administered Intramuscularly at One or Two Time Points in Healthy Human Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 14 Dec 2022
Price :
$35
*
At a glance
- Drugs Human butyrylcholinesterase (Primary)
- Indications Poisoning
- Focus Adverse reactions
- Sponsors PharmAthene
- 23 May 2014 New trial record